Finland· FI-REL-REL61952

Afqlir

A aflibercept product containing aflibercept, registered in Finland by Sandoz GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC S01LA05

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedAfqlirATCS01LA05REGISTER NO.FI-REL-REL61952PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Aflibercept is registered in 11 of 19 countries.

Countries holding a registration under ATC S01LA05 (aflibercept), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Aflibercept · ATC S01LA05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Aflibercept
Manufacturer
Sandoz GmbH
Country
Finland (FI)
ATC code
S01LA05
ATC class
Aflibercept
Defined daily dose
0.018 DE, IVT
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Aflibercept in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aflibercept products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Vgenfli
  • Iceland · Afiveg, Afqlir
  • Liechtenstein · Afiveg, Afqlir
  • Norway · Afiveg, Afqlir

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d12dae2a-331c-4acb-ac10-6f874be5e966
GET /v1/drugs/d12dae2a-331c-4acb-ac10-6f874be5e966?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektioneste, liuos, esitäytetty ruisku",
  "route": "Silmän lasiaiseen",
  "ddd_unit": null,
  "strength": "40 mg/ml",
  "atc_label": "aflibersepti",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/24/1867/001",
  "fimea_rel_id": "REL61952",
  "authorised_at": "2024-11-13"
}

See everything about aflibercept.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.